Lv4
530 积分 2024-02-21 加入
587 Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: Data from the phase 3 guide trial
1个月前
已完结
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
1个月前
已完结
Epidemiology of acne vulgaris
1个月前
已完结
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial
2个月前
已完结
75120 Efficacy of Picankibart among Difference BMI and Body Weight in Adult Plaque Psoriasis: Subgroup Analyses of the Phase 3 CLEAR-1 Trial
3个月前
已关闭
Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis
4个月前
已完结
Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board
4个月前
已完结
61865 Guselkumab demonstrates effectiveness regardless of disease duration: Week 76 results from the real-world G-EPOSS study
5个月前
已关闭
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
5个月前
已完结
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
5个月前
已完结